News
12-15-2008, 06:30 AM
Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast cancer tumor recurrence test, MammaPrint(R), was used to differentiate between patients at high and low risk for recurrence.
More... (http://www.medicalnewstoday.com/articles/133008.php)
More... (http://www.medicalnewstoday.com/articles/133008.php)